767 related articles for article (PubMed ID: 24084047)
1. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.
Tai S; Fantegrossi WE
Curr Top Behav Neurosci; 2017; 32():249-262. PubMed ID: 28012093
[TBL] [Abstract][Full Text] [Related]
3. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
Castaneto MS; Gorelick DA; Desrosiers NA; Hartman RL; Pirard S; Huestis MA
Drug Alcohol Depend; 2014 Nov; 144():12-41. PubMed ID: 25220897
[TBL] [Abstract][Full Text] [Related]
4. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
Rajasekaran M; Brents LK; Franks LN; Moran JH; Prather PL
Toxicol Appl Pharmacol; 2013 Jun; 269(2):100-8. PubMed ID: 23537664
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
[TBL] [Abstract][Full Text] [Related]
6. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.
Brents LK; Reichard EE; Zimmerman SM; Moran JH; Fantegrossi WE; Prather PL
PLoS One; 2011; 6(7):e21917. PubMed ID: 21755008
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Cannabinoids.
Mills B; Yepes A; Nugent K
Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
[TBL] [Abstract][Full Text] [Related]
8. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?
Seely KA; Prather PL; James LP; Moran JH
Mol Interv; 2011 Feb; 11(1):36-51. PubMed ID: 21441120
[TBL] [Abstract][Full Text] [Related]
9. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ
Hoffman AF; Lycas MD; Kaczmarzyk JR; Spivak CE; Baumann MH; Lupica CR
Addict Biol; 2017 Mar; 22(2):390-399. PubMed ID: 26732435
[TBL] [Abstract][Full Text] [Related]
10. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018.
Su MK; Seely KA; Moran JH; Hoffman RS
Clin Pharmacol Ther; 2015 Jun; 97(6):562-4. PubMed ID: 25788107
[TBL] [Abstract][Full Text] [Related]
12. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.
Brents LK; Gallus-Zawada A; Radominska-Pandya A; Vasiljevik T; Prisinzano TE; Fantegrossi WE; Moran JH; Prather PL
Biochem Pharmacol; 2012 Apr; 83(7):952-61. PubMed ID: 22266354
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.
Tai S; Fantegrossi WE
Curr Addict Rep; 2014 Jun; 1(2):129-136. PubMed ID: 26413452
[TBL] [Abstract][Full Text] [Related]
14. "Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays.
Järbe TU; Gifford RS
Life Sci; 2014 Feb; 97(1):64-71. PubMed ID: 23891559
[TBL] [Abstract][Full Text] [Related]
15. Potential Mechanisms Underlying the Deleterious Effects of Synthetic Cannabinoids Found in Spice/K2 Products.
Basavarajappa BS; Subbanna S
Brain Sci; 2019 Jan; 9(1):. PubMed ID: 30654473
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
17. Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.
Thomas BF; Lefever TW; Cortes RA; Grabenauer M; Kovach AL; Cox AO; Patel PR; Pollard GT; Marusich JA; Kevin RC; Gamage TF; Wiley JL
J Pharmacol Exp Ther; 2017 Apr; 361(1):162-171. PubMed ID: 28087785
[TBL] [Abstract][Full Text] [Related]
18. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Pot: Not Your Grandfather's Marijuana.
Ford BM; Tai S; Fantegrossi WE; Prather PL
Trends Pharmacol Sci; 2017 Mar; 38(3):257-276. PubMed ID: 28162792
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.
Marusich JA; Gamage TF; Zhang Y; Akinfiresoye LR; Wiley JL
Pharmacol Biochem Behav; 2022 Oct; 220():173467. PubMed ID: 36154844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
